Patients With Advanced NSCLC Face Critical Treatment Gaps

New research reveals critical gaps in treatment for advanced non–small cell lung cancer (NSCLC), emphasizing the need for innovative therapies to improve patient outcomes.

Read the full article here

Related Articles

LISTEN TO THE EXPERTS

Sponsored by Novartis US Medical Affairs Elevated lipoprotein(a) (Lp[a]) represents the most common type of genetic dyslipidemia. 1 Elevated Lp(a) levels occurring in 20% of…